Navigation Links
Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
Date:5/16/2008

NEW YORK, May 16 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced details of the methodology and purpose of its Phase I Human Trials with its PulmoBind Molecular Imaging technology for the diagnosis of Pulmonary Embolism and Pulmonary Hypertension.

The work will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc., and the title of the work is: "Phase I Study of the Use of PulmoBind for Molecular Imaging of the Pulmonary Circulation."

The study will be a single center, Phase 1 safety and efficacy study of a single intravenous injection of PulmoBind in human subjects with no history of lung disease.

The Outcomes will be:

1. Safety -- to determine pharmacokinetics and biodistribution of

PulmoBind in humans and to perform dosimetric evaluation

2. Efficacy -- to evaluate the ability of PulmoBind to allow lung

perfusion imaging in humans

Pulmo BioTech expects this work to be completed by late summer 2008.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Pulmo BioTech's mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.

The company was conceived within the Montreal Heart Institute "MHI" (a world renowned h
'/>"/>

SOURCE Pulmo BioTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
2. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
3. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
4. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
5. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
6. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
7. Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Strykers Biotech Division Receives FDA Warning Letter
10. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
11. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , TORONTO, Nov. 30 The Spec...Inc. ("Patheon" or the "Company") (TSX: PTI) and J...oldings, LLC (collectively, "JLL"), today announce...tlement agreement in respect of the pending legal ...t provides among other things that: ,, until M...
(Date:11/30/2009)..., , MELVILLE, N.Y., Nov. 30 /PRNewswire-Fir...he largest provider of health care products and se...Company,s Executive Vice President and Chief Finan...Investor Program on Tuesday, December 1, 2009. Th...in London. ,, Henry Schein,s presentation is s...
(Date:11/30/2009)..., , MT. LAUREL, N.J., Nov. 30 /PRNewswire-Fi...ing provider of technology-enabled clinical docume...ed an agreement with Nuance Communications, Inc. (...ce,s SpeechMagic speech recognition engine and pro...icine(TM), MedQuist,s front-end speech recognition...
Breaking Medicine Technology:Patheon and JLL Partners Announce Litigation Settlement 2Patheon and JLL Partners Announce Litigation Settlement 3Henry Schein to Present at the NASDAQ OMX 23rd Investor Program 2MedQuist Signs Agreement Extending Use of Real-Time Speech Recognition Engine to Wide Range of Medical Specialties 2California Health Insurance Assistance Program Awarded 2009 Grant Funding Says MedicareSupplementPlans com 52178 1California Health Insurance Assistance Program Awarded 2009 Grant Funding Says MedicareSupplementPlans com 52178 2FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 1FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 2FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 3FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 4FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 5FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 6FDA Approves Tekturna HCT 28R 29 as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent 4755 7ISSA Announces New Specialist in Fitness Nutrition Certification 52175 1ISSA Announces New Specialist in Fitness Nutrition Certification 52175 2
...x Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlant...ay announced its financial results and provided an...r 30, 2007. Financial Results for the Quarter End...loss of $1,165,509 for the three months,ended Sept...period in 2006.,For the nine months ended Septembe...
...RISBANE, Calif., Nov. 15 BiPar,Sciences, Inc., a ...g novel,cancer therapies, today announced it has i...r, BSI-201, in patients with triple-negative breas...erone or HER2 receptors. The company designed the... a major unmet medical need-based on molecular bio...
Other Medicine Technology:GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 6GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 7GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 8GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 9GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 10BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 3
(Date:11/30/2009)...While recognizing significant impact, CBO analysis... /PRNewswire-USNewswire/ -- The Blue Cross and B...g statement regarding the estimate released today ...e CBO today confirmed what many economists, actuar...: the Senate healthcare reform bill would make cov...
(Date:11/30/2009)...letes had ,younger, immune cells than sedentary, h...althDay News) -- Studies have shown that exercise ...w new research shows that the reason why may be fo...etes had longer telomeres -- DNA at the tips of ch...blood cells than healthy, nonsmoking adults who di...
(Date:11/30/2009)..., CARDIFF, Calif., Nov. 30 /PRNewswire-FirstCall/ ...mindinc.com) is pleased to announce the Company,s ...lable for purchase. The game, "Think-Tac-Toe" is t...y the game with the power of their mind and is gea...old online at a price of $49 and can be purchased ...
(Date:11/30/2009)... , NEW YORK, Nov. 30 Of the mor... are living with HIV/AIDS, nearly half are African...in Washington, D.C. have surpassed the threshold f...men account for more than 90 percent of all women ...n Tuesday, December 1 at 6:00 p.m.*, World AIDS Da...
(Date:11/30/2009)...t., November 30, 2009 ― Providing free medic...s to patients, lives at a relatively low cost for ...y researchers at St. Michael,s Hospital in Toronto...ctive prescribed medications because they simply d...lla, the study,s lead author and a physician at St...
Breaking Medicine News(10 mins):Health News:CBO Confirms That Premiums Will Increase Under the Senate Healthcare Reform Bill 2Health News:Exercise Guards White Blood Cells Against Aging 2Health News:Exercise Guards White Blood Cells Against Aging 3Health News:First Thought-Controlled Game Complete From Jedi Mind, Inc. 2Health News:BET Networks Joins the International Call to Stop the Spread of HIV on World Aids Day Tuesday, December 1 with an Annual Special Episode of '106 & PARK' and on the Ground Initiatives Through BET's Award Winning Public Affairs Campaign Rap-It-Up 2Health News:BET Networks Joins the International Call to Stop the Spread of HIV on World Aids Day Tuesday, December 1 with an Annual Special Episode of '106 & PARK' and on the Ground Initiatives Through BET's Award Winning Public Affairs Campaign Rap-It-Up 3Health News:Coverage of inexpensive drugs may increase length and quality of life after heart attack 2
...Ill., July 8 Healthation, a healthcare,technology...year Software,as a Service agreement with Health P... than 140,000 members in southeastern Pennsylvania...,administration capabilities to its provider commu...
...ion people suffer from preventable, treatable dise...ny, medical director Global Health Progress, TOYA...ndustry is joining the World Health Organization (... threat,and a major strain on the economic viabili...
...ON, July 8 At a U.S. House,Government Oversight S...p,called on Congress to stop dental mercury pollut...nstall amalgam separators, and holding manufacture...algam is over," said Michael,Bender, director of t...
... July 8 Bristol-Myers Squibb, an,international ph...e output,of ozone-depleting refrigerants at multip...ombined cost of $3.65 million to resolve violation...rt in Evansville, Ind., New,York-based Bristol-Mye...
...ar disorder is one of the most complex and challen...rder is typically associated with considerable acu...ted in the course of illness with times of tremend...e disorder is called bipolar, because depressive a...
... help identify which patients are most likely to r...ealthDay News) -- A genetic test to determine whet...o treatment with the drug Herceptin (trastuzumab) ...egulates the growth of cancer cells, are in tumor ...
Other Medicine News:Health News:Health Partners Chooses Healthation's AboveHealth Provider Portal 2Health News:Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases 2Health News:Congress Called on to Hold Dental Mercury Polluters Accountable at U.S. House Oversight Hearing 2Health News:Bristol-Myers Squibb Agrees to Clean Air Act Upgrades 2Health News:Bristol-Myers Squibb Agrees to Clean Air Act Upgrades 3Health News:The ECNP consensus statement on bipolar depression 2Health News:FDA Approves Genetic Test for Breast Cancer 2
Vertebral Body Replacement (VBR)
Vertigraft Femoral Shaft
...ackable cage system provides anterior column suppo...vertebrectomies from T1 to L5. The system consists...at are stacked to a desired height, accommodating ...orced polymer material emulates the biomechanical ...
... bone void filler is an extrudable, moldable bone ...se anywhere in the skeletal system, including extr...sorbable, serving as a temporary scaffolding for n...visible on X-ray, making healing easier to assess....
Medicine Products: